Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 67Cyclophosphamide 39Vincristine 33Prednisone 31Doxorubicin 25Lenalidomide 18Radiotherapy 16Bendamustine Hydrochloride 14Peripheral Blood Stem Cell Transplantation 10Filgrastim 10Etoposide 10Prednisolone 8tofacitinib 7obinutuzumab 6ibritumomab tiuxetan 6fludarabine 6VAP-cyclo protocol 6Mitoxantrone 6Methylprednisolone 6Deoxycholic Acid 6Cytarabine 6Melphalan 5Dexamethasone 5Carmustine 5ibrutinib 4fludarabine phosphate 4R-CHOP protocol 4Methotrexate 4Interferon-alpha 4Idarubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Follicular × tafasitamab × Clear all
NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡